Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

2.4K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.4K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

226
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
226
Drug Discovery: Overview01:26

Drug Discovery: Overview

8.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

262
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
262
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

257
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
257
Pharmacodynamics: Overview and Principles01:21

Pharmacodynamics: Overview and Principles

2.1K
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Helping Underdeveloped Lungs with Cells (HULC-2): mesenchymal stromal cells in extreme preterm infants at risk of developing bronchopulmonary dysplasia - a study protocol of a phase 2 multicentre double blind randomised controlled trial in Canada.

BMJ open·2026
Same authorSame journal

Repair of Sinus Venosus Atrial Septal Defect in 2 Patients With Severe Pulmonary Arterial Hypertension.

Pulmonary circulation·2026
Same author

Premature Ventricular Contractions as a Target for Arrhythmogenic Right Ventricular Cardiomyopathy Trials PVC in ARVC trials.

Heart rhythm·2026
Same author

Assessing the real-world effects of prophylactic hydrocortisone in the Canadian Neonatal Network: A cohort study.

Journal of perinatology : official journal of the California Perinatal Association·2026
Same author

Extracorporeal Membrane Oxygenation in Pediatric Pulmonary Hypertension: A Single-Center Cohort to Inform Decision-Making.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same author

A biomimetic miniaturized in vitro model to target early markers of neonatal pulmonary vascular injury.

American journal of physiology. Lung cellular and molecular physiology·2026

Related Experiment Video

Updated: Sep 15, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.3K

Enhancing Drug Development for Paediatric Pulmonary Hypertension-An Integrative Perspective.

Steven H Abman1, Sylvia M Nikkho2, Rolf M F Berger3

  • 1Department of Paediatrics, Paediatric Heart Lung Center University of Colorado School of Medicine Aurora Colorado USA.

Pulmonary Circulation
|July 17, 2025
PubMed
Summary
This summary is machine-generated.

Developing effective treatments for paediatric pulmonary hypertension (PH) requires innovative clinical trials. Leveraging registry data and collaboration can reduce off-label drug use and improve care for children with PH.

Keywords:
clinical trial designdrug developmentextrapolationpaediatric endpoints and biomarkerspaediatric pulmonary hypertension

More Related Videos

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
09:23

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension

Published on: February 11, 2017

16.9K
Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

324

Related Experiment Videos

Last Updated: Sep 15, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.3K
Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
09:23

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension

Published on: February 11, 2017

16.9K
Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

324

Area of Science:

  • Pediatric Pulmonology
  • Clinical Trial Design
  • Regulatory Science

Background:

  • Paediatric pulmonary hypertension (PH) presents high morbidity and mortality, with limited evidence-based therapies.
  • Current paediatric PH treatment relies heavily on adult data and small observational studies, often involving off-label drug use.
  • Challenges include defining paediatric PH phenotypes, lack of age-specific endpoints, and small patient populations.

Purpose of the Study:

  • To review integrated international perspectives on designing future clinical trials for paediatric PH.
  • To identify opportunities for improving evidence-based treatment protocols for paediatric PH.
  • To address regulatory and scientific challenges in paediatric PH drug development.

Main Methods:

  • Review of integrated international perspectives from academia, industry, and regulatory agencies.
  • Discussion of challenges in paediatric PH clinical trials, including safety, pharmacokinetics, and pharmacodynamics.
  • Exploration of innovative trial designs, real-world data, and biomarker potential.

Main Results:

  • Few drugs are comprehensively studied in neonates, infants, and children with PH.
  • Lack of regulatory-approved studies for safety and pharmacokinetics in young children is a significant gap.
  • Opportunities exist in innovative trial designs, registry data utilization, and multi-stakeholder collaboration.

Conclusions:

  • Innovative clinical trial designs and leveraging paediatric PH registry data are crucial for evidence-based treatment.
  • Reducing reliance on off-label drug use is essential for improving paediatric PH patient care.
  • Ongoing evaluation and adaptation of strategies are necessary to ensure the highest standard of care for paediatric PH patients.